Premier Path Wealth Partners’s Regeneron Pharmaceuticals REGN Stock Holding History

Premier Path Wealth Partners’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$316K	Sell	507 -160	-24%	-$109K	0.04%	355
2026 Q1	$515K	Buy	667 +130	+24%	+$99.5K	0.07%	266
2025 Q4	$414K	Buy	+537	New	+$365K	0.05%	275
2025 Q2	–	Sell	-344	Closed	-$218K	–	396
2025 Q1	$218K	Buy	+344	New	+$237K	0.03%	354
2024 Q4	–	Sell	-625	Closed	-$657K	–	384
2024 Q3	$657K	Buy	625 +5	+0.8%	+$5.56K	0.1%	201
2024 Q2	$651K	Buy	620 +62	+11%	+$60.1K	0.11%	188
2024 Q1	$537K	Buy	558 +42	+8%	+$39.9K	0.1%	200
2023 Q4	$453K	Buy	+516	New	+$425K	0.1%	202

Other funds holding REGN

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

MCI

McDonald Capital Investors Orinda, California $1.37B AUM 1.88% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Retirement Systems of Alabama Montgomery, Alabama $33.2B AUM 38.15% 1-Year Est. Return

New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

Parnassus Investments San Francisco, California $37.4B AUM 35.42% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

Premier Path Wealth Partners's REGN Position: Q2 2026 in Review

Premier Path Wealth Partners reduced its Regeneron Pharmaceuticals (REGN) stake by 24% in Q2 2026, selling an estimated $109K and leaving 507 shares worth $316K. The position accounts for 0.04% of the portfolio, ranked #355.

Premier Path Wealth Partners first reported a position in REGN in Q4 2023 and has held it in 8 quarters since. The position peaked at $657K in Q3 2024. 481 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

Premier Path Wealth Partners held 507 shares of Regeneron Pharmaceuticals worth $316K as of Q2 2026.
Premier Path Wealth Partners sold 160 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $109K.
Regeneron Pharmaceuticals made up 0.04% of Premier Path Wealth Partners's portfolio in Q2 2026, its #355 holding.
Premier Path Wealth Partners first reported a position in Regeneron Pharmaceuticals in Q4 2023 and has held it in 8 quarters since.
Premier Path Wealth Partners's Regeneron Pharmaceuticals position peaked at $657K in Q3 2024.
481 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Premier Path Wealth Partners's 13F filing for Q2 2026, filed 21 Jul 2026.